Back to Search
Start Over
Efficacy of Etanercept in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
- Source :
- Cutis; Jun2021, Vol. 107 Issue 6, pE22-E28, 7p, 2 Charts
- Publication Year :
- 2021
-
Abstract
- It has been suggested that the use of etanercept for treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) might provide improved mortality benefit and decreased skin healing times. This retrospective study compared the use of single-dose subcutaneous etanercept to intravenous immunoglobulin (IVIG) and supportive care alone. Thirteen patients were treated with a single dose (50 mg) of subcutaneous etanercept. Results of this study support the use of etanercept as a potentially beneficial agent in the treatment of SJS/TEN. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00114162
- Volume :
- 107
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- Cutis
- Publication Type :
- Academic Journal
- Accession number :
- 172969637
- Full Text :
- https://doi.org/10.12788/cutis.0288